
Opinion|Videos|May 3, 2024
Overcoming Limitations and Barriers Associated with Treating Pulmonary Arterial Hypertension
Author(s)Ioana Preston, MD
An expert on pulmonary arterial hypertension discusses the limitations of current therapies and the barriers to early diagnosis.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- What are the limitations of current pulmonary arterial hypertension (PAH) therapies that primarily focus on symptom management, and how do they impact patient outcomes?
- How does the high disease burden associated with PAH affect patients' quality of life and functional status?
- What are the barriers to early diagnosis and initiation of treatment for PAH, and how do they contribute to poor outcomes?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Physician Peer Influence Drives Uptake of Opportunistic Salpingectomy for Ovarian Cancer Prevention
2
CAR T-Cell Therapy Holds Potential in SCLC, but Significant Barriers Remain
3
Value-Based Care Interventions and Management of CKD Progression
4
Defining the Role of Rilzabrutinib in ITP Management
5